FDA INVESTIGATING RECALLED ELDEPRYL LOT
Executive Summary
FDA INVESTIGATING RECALLED ELDEPRYL LOT because of "lack of assurance of product origin and authenticity." A Class II recall of the MAO-B inhibitor for Parkinson's disease began in September. Somerset Pharmaceuticals, the 50/50 Mylan/Circa joint venture that markets Eldepryl (selegiline), said Jan. 4 that some of the recalled product is "definitely counterfeit."